Sensei Biotherap Rg
Clinical‑stage biotech Sensei Biotherapeutics focuses on tumor‑microenvironment‑targeted antibodies, including Phase 1/2 VISTA blocker Solnerstotug and bispecific CD28 leader SNS‑201, aiming to capture the solid‑tumor immuno‑oncology market.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 14
- HQ: Rockville
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.